Les candidats-vaccins contre le COVID-19 testés chez l’humain sont listés au bas de cette page.

Jusqu’à présent, la Confédération a conclu des contrats avec cinq fabricants : Moderna (désormais 20,5 millions de doses au total), Pfizer/BioNTech (6 millions de doses environ), AstraZeneca (5,3 millions de doses environ) et désormais Curevac (5 millions de doses) ainsi que Novavax (6 millions de doses). Cette manière de faire permet de garantir que même en cas de difficultés de livraison, la population dispose de suffisamment de doses d’un vaccin autorisé. La Confédération poursuit les négociations avec différents fabricants, car il est difficile d’évaluer comment la pandémie évoluera. 
 
Les publications scientifiques (peer-reviewed) et/ou communiqués de presse disponibles pour ces vaccins sont les suivants.
 
mRNA-1273 (vaccin à ARNm, Moderna et National Institute of Allergy and Infectious Diseases et Moderna)

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (New England Journal of Medicine, 14.7.2020)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (New England Journal of Medicine, 29.9.2020)

Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization (Press release, 30.11.2020)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (New England Journal of Medicine, 4.12.2020)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (New England Journal of Medicine, 30.12.2020)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine (Vaccine, 9.2.2021)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (New England Journal of Medicine, 6.4.2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (New England Journal of Medicine, 7.4.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern (Press release, 5.5.2021)

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June (Press release, 25.5.2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines (New England Journal of Medicine, 30.6.2021)

 

BNT162b2 (vaccin à ARNm, BioNTech RNA Pharmaceuticals et Pfizer)

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (1.7.2020)

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Nature, 12.8.2020)

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses (Nature, 30.9.2020)

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (New England Journal of Medicine, 14.10.2020)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (New England Journal of Medicine, 10.12.2020)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (New England Journal of Medicine, 24.2.2021)

Neutralizing Activity of BNT162b2-Elicited Serum (New England Journal of Medicine, 8.3.2021)

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study (Press release, 1.4.2021)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 (New England Journal of Medicine, 7.4.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study (Nature Medicine, 22.4.2021)

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study (Lancet, 23.4.2021)

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study (Lancet, 23.4.2021)

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (Lancet Infectious Diseases, 27.4.2021)

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data (Lancet, 5.5.2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants (New England Journal of Medicine, 5.5.2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants (New England Journal of Medicine, 12.5.2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (New England Journal of Medicine, 27.5.2021)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination (The Lancet, 3.6.2021)

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness (The Lancet, 14.6.2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines (New England Journal of Medicine, 30.6.2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 (The Lancet, 15.7.2021)

 

AZD1222 (ChAdOx1 nCoV-19) (vaccin à vecteur, Astra Zeneca et University of Oxford)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (The Lancet 20.7.2020)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (The Lancet, 18.11.2020)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (The Lancet, 8.12.2020)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial et Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (Nature Medicine, 17.12.2020)

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (The Lancet, 19.2.2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (New England Journal of Medicine, 16.3.2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (The Lancet, 30.3.2021)

Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? (The Lancet, 30.3.2021)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (New England Journal of Medicine, 9.4.2021)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (New England Journal of Medicine, 9.4.2021)

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study (The Lancet, 23.4.2021)

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study (Lancet Infectious Diseases, 27.4.2021)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC (The Lancet, 28.6.2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 (The Lancet, 15.7.2021)

 

Les vaccins de Moderna, Pfizer/BioNTech et AstraZeneca ayant déjà été homologués dans certains pays, un résumé des résultats intérmédiaires des essais de phase 3 déjà disponibles pour ces vaccins est disponible ICI.

 
CVnCoV Vaccine (vaccin à ARNm, Curevac)
 
 
 
 
 
 
NVX-CoV2373 (protéines recombinantes, Novavax)

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (New England Journal of Medicine, 2.9.2020)

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial (Press release, 28.1.2021)

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials (Press release, 11.3.2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (New England Journal of Medicine, 7.4.2021)

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (New England Journal of Medicine, 5.5.2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant (medRxiv, 14.5.2021)

Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine (Press release, 11.6.2021)

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine (New England Journal of Medicine, 30.6.2021)

 
 
 
Autres vaccins déjà en Phase III (efficacité et sécurité):
 
Remarque: certains de ces vaccins ont déjà été homologués dans certains pays. Pour une liste actualisée des vaccins en phases d'essais cliniques, consulter ce document de l'OMS, régulièrement mis à jour.
 

  Inactivated SARS-CoV-2 (virus inactivés, Sinovac et Butantan Institute)

Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (virus inactivés, Hennan Provincial Center for Disease Control and Prevention et Sinopharm)

- BBIBP-CorV (virus inactivés, Beijing Institute of Biological Products Co., LTD et Laboratorio Elea Phoenix S.A.)

- Ad26.COV2.S (vaccin à vecteur, Janssen Vaccines & Prevention (Johnson & Johnson))

Ad5-nCoV (vaccin à vecteur, CanSino Biologics)

- Gam-COVID-Vac (vaccin à vecteur, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation)

- Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) (virus inactivés, Wuhan Provincial Center for Disease Control and Prevention)

- CoVLP (protéines recombinantes, Medicago)

BBV152 - COVAXIN (virus inactivés, Bharat Biotech International Ltd)

Recombinant new coronavirus vaccine (CHO cell) (protéines recombinantes, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.)

- AG0302-COVID19 (vaccin à ADN, AnGes Inc., Japan Agency for Medical Research and Development)

Inactivated SARS-CoV-2 Vaccine (virus inactivés, Chinese Academy of Medical Sciences)

- SCB-2019 (protéines recombinantes, Clover Biopharmaceuticals Australia)

nCov Vaccine (vaccin à ADN, Cadila Healthcare Ltd)

- QazCovid-in (virus inactivés, Research Institute for Biological Safety Problems)

- UB-612 (protéines recombinantes, United Biomedical, COVAXX)

- EpiVacCorona (protéines recombinantes, Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector")

 Liste continuellement mise à jour des candidats vaccins en phase III (en anglais)

 


Liste de tous les vaccins en phase I, II ou III, classés par type:

  • 1

Labels HONcode

Ce site respecte les principes de la charte HONcode Ce site respecte les principes de la charte HONcode

Voir le certificat

Ce site a été certifié par l'Organisation mondiale de la santé (OMS) comme remplissant tous les critères de bonne pratique en matière d'information sur les vaccinations.

En savoir plus...